trial · primary record
Fezolinetant
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 92 |
| Primary completion | 2028-03 |
| Primary endpoint | Frequency of moderate/severe VMS at 12 weeks of treatment with fezolinetant vs. placebo |
| Registry ID | NCT06917313 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:56:15.181Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06917313
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Fezolinetant · approval
- Fezolinetant · compound